Molecular antigen arrays

Details Molecular antigen arrays Molecular antigen arrays

2006-11-21

2006-11-21

Mosher, Mary E. (Department: 1648)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S235100, C435S252300, C435S252330, C435S320100, C536S023720

Reexamination Certificate

active

07138252

ABSTRACT:
The present invention provides a composition comprising an AP205 virus like particle (VLP) and an antigen. The invention also provides a process for producing an antigen or antigenic determinant bound to AP205 VLP. AP205 VLP bound to an antigen is useful in the production of compositions for inducing immune responses that are useful for the prevention or treatment of diseases, disorders or conditions including infectious diseases, allergies, cancer, drug addiction, poisoning and to efficiently induce self-specific immune responses, in particular antibody responses.

REFERENCES:
patent: 4722840 (1988-02-01), Valenzuela et al.
patent: 4918166 (1990-04-01), Kingsman et al.
patent: 5071651 (1991-12-01), Sabara et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5334394 (1994-08-01), Kossovsky et al.
patent: 5374426 (1994-12-01), Sabara et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5698424 (1997-12-01), Mastico et al.
patent: 5739026 (1998-04-01), Garoff et al.
patent: 5766602 (1998-06-01), Xiong et al.
patent: 5770380 (1998-06-01), Hamilton et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 5792462 (1998-08-01), Johnston et al.
patent: 5814482 (1998-09-01), Dubensky, Jr. et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 5928647 (1999-07-01), Rock
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 6004763 (1999-12-01), Gengoux et al.
patent: 6054312 (2000-04-01), Larocca et al.
patent: 6231864 (2001-05-01), Birkett
patent: 6380364 (2002-04-01), Mueller et al.
patent: 2002/0064533 (2002-05-01), Murray
patent: 2002/0081295 (2002-06-01), Schiller et al.
patent: 2003/0157479 (2003-08-01), Bachmann et al.
patent: 2003/0175290 (2003-09-01), Renner et al.
patent: 2003/0175711 (2003-09-01), Renner et al.
patent: 0 259 149 (1993-12-01), None
patent: 0 385 610 (1994-03-01), None
patent: 0 465 081 (1994-04-01), None
patent: 0 283 505 (1994-07-01), None
patent: 0 425 082 (1995-04-01), None
patent: WO 92/11291 (1992-07-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 94/15585 (1994-07-01), None
patent: WO 96/05293 (1996-02-01), None
patent: WO 96/30523 (1996-10-01), None
patent: WO 97/31948 (1997-09-01), None
patent: WO 98/15631 (1998-04-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 99/28478 (1999-06-01), None
patent: WO 99/40934 (1999-08-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/57289 (1999-11-01), None
patent: WO 99/67293 (1999-12-01), None
patent: WO 00/23955 (2000-04-01), None
patent: WO 00/32227 (2000-06-01), None
patent: WO 00/50461 (2000-08-01), None
patent: WO 00/59928 (2000-10-01), None
patent: WO 01/62284 (2001-08-01), None
patent: WO 01/85208 (2001-11-01), None
patent: WO 03/024481 (2003-03-01), None
patent: WO 02/056905 (2003-07-01), None
Klovins et al (Journal of General Virology 83:1523-1533, 2002).
Co-pending U.S. Appl. No. 10/264,267, inventors Bachmann, M., filed Oct. 4, 2002, not published.
Co-pending U.S. Appl. No. 10/289,456, inventors Bachmann et al., filed Nov. 7, 2002, not published.
Co-pending U.S. Appl. No. 10/346,190, inventors Bachmann et al., filed Jan. 17, 2003, not published.
Co-pending U.S. Appl. No. 10/622,064, inventors Bachmann et al., filed Jul. 18, 2003, not published.
Co-pending U.S. Appl. No. 10/622,087, inventors Bachmann et al., filed Jul. 18, 2003, not published.
Co-pending U.S. Appl. No. 10/622,124, inventors Bachmann et al., filed Jul. 18, 2003, not published.
Chackerian B., et al., “Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles,”Proc. Natl. Acad. Sci. USA 96:2373-2378, National Academy Press (Mar. 1999).
Gardiner, S.M., et al., “Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats,”Br. J. Pharmacol. 129:1178-1182 (Mar. 2000).
Hermanson, G.T., inBioconjugate Techniques, Academic Press, San Diego, CA, pp. 1-296 (1996).
Jeannin, P., et al., “Immunogenicity and antigenicity of synthetic peptides derived from the mite allergenDer p I,” Mol. Immunl. 30:1511-1518, Pergamon Press, Ltd. (1993).
Klovins, J., et al., “Nucleotide sequence of a ssRNA phage fromAcinebacter: kinship to coliphages,”J. Gen. Virol. 83:1523-1533, Society For General Microbiology (Jun. 2002).
Sutcliffe, J.G., et al., “Complete nucleotide sequence of theEsherichia coliPlasmid pBR322,”Cold Spring Harb. Symp. Quant. Biol. 43:77-90, Cold Spring Harbor Laboratory Press (1979).
Jegerlehner, A., et al., “A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses,”Vaccine 20:3104-3112, Elsevier Science, Ltd. (Aug. 2002).
The Biology of Animal Viruses, 2nd ed., Fenner, F., et al., eds., Academic Press, New York, NY, pp. 117-119 (1974).
NCBI Entrez, PubMed Abstract, PMID: 2205968, Diallo, A., et al., “Morbillivirus group: genome organization and proteins,”Vet. Microbiol. 23:155-163 (1990).
Lechner F. et al., “Virus-Like Particles as a Modular System for Novel Vaccines,”Intervirology 45:212-217, S. Karger AG, Basel (Jul. 2002).
Brown, William L. et al., “RNA Bacteriophage Capsid-Mediated Drug Delivery and Epitope Presentation,”Intervirology 45:371-380, S. Karger AG, Basel (Jul. 2002).
International Search Report for PCT/EP 03/07572, European Patent Office, The Netherlands (Dec. 2003).
Abraham, J.M., et al., “An invertible element of DNA controls phase variation of type 1 fimbriae ofEscherichia coli,” Proc. Natl. Acad. Sci. USA 82:5724-5727, National Academy Press (1985).
Abraham, S.N., et al., “Glycerol-Induced Unraveling of the Tight Helical Conformation ofEscherichia coliType 1 Fimbriae,”J. Bacteriol. 174:5145-5148, American Society for Microbiology (1992).
Adhin, M.R., et al., “Nucleotide Sequence from the ssRNA Bacteriophage JP34 Resolves the Discrepancy between Serological and Biophysical Classification,”Virology 170:238-242, Academic Press, Inc. (1989).
Aguzzi, A., “Prion diseases, blood and the immune system: concerns and reality,”Haematologica 85:3-10, Il Pensiero Scientifico Editore (Jan. 2000).
Ansel, K.M., et al., “In Vivo-activated CD4 T Cells Upregulate CXC Cheomkine Receptor 5 and Reprogram Their Response to Lymphoid Chemokines,”J. Exp. Med. 190:1123-1134, The Rockefeller University Press (1999).
Ansel, K.M., et al., “A chemokine-driven positive feedback loop organizes lymphoid follicles,”Nature 406:309-314, Nature Publishing Group (Jul. 2000).
Antonysamy, M.A., et al., “Evidence for a Role of IL-17 in Organ Allograft Rejection: IL-17 Promotes the Functional Differentiation of Dendritic Cell Progenitors,”J. Immunol. 162:577-584, The American Association of Immunologists (1999).
Arenberg, D.A., et al., “The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model,”Cancer Immunol. Immunother. 49:587-592, Springer-Verlag (Jan. 2001).
Arnon, R., et al., “A mimotope peptide-based vaccine againstSchistosoma mansoni: synthesis and characterization,”Immunology 101:555-562, Blackwell Science, Ltd. (Dec. 2000).
Bachmann, M.F., and Zinkernagel, R.M., “The influence of virus structure on antibody responses and virus serotype formation,”Immunol. Today 17:553-558, Elsevier Science, Ltd. (1996).
Bachmann, M.F., and Zinkernagel, R.M., “Neutralizing Antiviral B Cell Responses,”Annu. Rev. Immunol. 15:235-270, Annual Reviews, Inc. (1997).
Bachmann, M.F., et al., “TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand-independent T Helper Cell Activation,”J. Exp. Med. 189:1025-1031, The Rockefeller University Press (1999).
Banerjee, R.R., and Lazar, M.A., “Dimerization of Resistin and Resistin-like Molecules Is Determined by a Single Cysteine,”J. Biol. Chem. 276:25970-25973, The American Society

Affiliated with

Also associated with

Rating

Molecular antigen arrays does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Molecular antigen arrays, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Molecular antigen arrays will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3681536